Recent Updates — CTOR
Citius Oncology reported preliminary, unaudited FY2026 fourth-quarter data showing a 120% increase in LYMPHIR (denileukin diftitox-cxdl) unit sales to U.S. wholesalers compared to the prior quarter. The company sold 792 units during the three months ended September 30, 2026, up from 360 units in the fiscal third quarter. Institutional vial orders also rose slightly to 950 vials from 926. As of the report date, 54 institutions have ordered LYMPHIR, an increase from 44 previously reported. The company expects complete results in its December 2026 annual filing. Citius Oncology is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.
The Nasdaq Stock Market granted Citius Oncology an extension until April 19, 2027, to demonstrate compliance with the $1.00 per share minimum bid price requirement for continued listing on the Nasdaq Capital Market. If the stock closes at or above $1.00 for ten consecutive business days before that date, the company will regain compliance. Failure to meet this threshold by April 19, 2027, will result in a delisting notice, though the company retains the right to appeal to a Nasdaq hearings panel. The filing notes that the listing remains active during this period and the company is evaluating options to restore compliance. Citius Oncology operates as a clinical-stage biopharmaceutical company focused on developing oncology treatments.
Citius Oncology reported fiscal third quarter results ending June 30, 2026, generating $1.5 million in revenue for the quarter and $7.1 million for the first nine months of fiscal 2026, compared to zero in the prior year period. The company recorded a net loss of $8.9 million, or $(0.08) per share, for the quarter, driven by a $30.7 million general and administrative expense total that included a $19.7 million one-time CMO contract cancellation charge. Cash and cash equivalents stood at $16.6 million as of June 30, 2026, following approximately $9.7 million in net proceeds from warrant exercises and the funding of a $10.0 million tranche under a senior secured term loan facility. Institutional demand for its product LYMPHIR accelerated, with vial orders growing 31% sequentially to 926 units and 44 institutions now ordering the therapy. Citius Oncology is an oncology-focused biopharmaceutical company developing and commercializing targeted therapies.
Citius Oncology, Inc. announced the appointment of Jonathan Peri, Ph.D., J.D., as an independent Class I director to its Board of Directors, effective August 10, 2026. The Board expanded from eight to nine members following a unanimous vote by the Corporate Governance and Nominating Committee. Dr. Peri currently serves as President of Manor College and previously held leadership roles at Neumann University and First State Bank. He brings expertise in higher education administration, legal counsel, and corporate governance. Citius Oncology is an oncology-focused biopharmaceutical company developing and commercializing targeted therapies for cutaneous T-cell lymphoma.